Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506994 | 0.89 | KMT2A (0.35) | KDM4EMAPTL3MBTL1 | |
| SCHEMBL6503874 | 0.86 | KMT2A (0.36) | KDM4EALDH1A1 | |
| SCHEMBL6429803 | 0.85 | RAB9A (0.38) | KDM4EALDH1A1MAPT | |
| SCHEMBL6499622 | 0.85 | HPGD (0.35) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL6392731 | 0.84 | EPHX2 (0.33) | KDM4EALDH1A1MAPTL3MBTL1 | |
| SCHEMBL6503577 | 0.84 | ALDH1A1 (0.34) | KDM4EALDH1A1MAPTL3MBTL1 | |
| SCHEMBL6510626 | 0.82 | TDP1 (0.34) | ALDH1A1 | |
| SCHEMBL6508683 | 0.82 | SSTR3 (0.31) | — | |
| SCHEMBL6500555 | 0.82 | L3MBTL1 (0.35) | KDM4EALDH1A1MAPTL3MBTL1 | |
| SCHEMBL6505196 | 0.81 | MAPT (0.33) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005020987-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSES GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | KDM4E 2824/4885ALDH1A1 67/4885MAPT 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.